Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + lazertinib + platinum-pemetrexed chemotherapy versus platinum-pemetrexed chemotherapy after osimertinib failure in EGFR-mutated advanced non-small cell lung cancer
2023-506518-33-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of amivantamab, lazertinib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Planned start Nov 2021; status: authorised.
02
Drugs
amivantamablazertinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506518-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506518-33-00.